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2 
ABSTRACT   26 
Objective: Referral for colposcopy because of abnormal Pap test results is likely to be 27 
distressing, but the extent and duration of these effects are unknown. We aimed to fill this 28 
gap. 29 
Methods: We conducted a prospective observational study at two departments of Obstetrics 30 
and Gynecology (an academic and a non-academic setting). Women referred for colposcopy 31 
completed questionnaires before colposcopy, and at 1, 3, and 6 months afterwards. A 32 
reference group of 706 screen participants, aged 29-60 years old, was included and completed 33 
questionnaires once. Main outcome measures were generic health-related quality of life 34 
(HRQoL), assessed through the EQ-5D and the SF-12 physical and mental scores (PCS-12 and 35 
MCS-12); anxiety as assessed by STAI-6, and screen-specific anxiety as assessed by the 36 
Psychological Consequences Questionnaire (PCQ).  37 
Results 154 women responded to the questionnaire, of whom 132 were included in the 38 
analyses. Histological results were CIN 1 in 17/115 women (15%) and CIN 2+ in 62 (54%). In 36 39 
women (31%) there was no histologically confirmed neoplasia. Before colposcopy physical 40 
HRQoL scores were similar or slightly better than in the reference group, while mental HRQoL 41 
(MSC-12) and (screen-specific) anxiety were worse (p<0.001). Irrespective of CIN-grades, 42 
anxiety washed out during follow-up (p<0.001), with changes being clinically relevant.  43 
Conclusions Referral for gynecological evaluation because of abnormal PAP-test results was 44 
distressing. Anxiety - and not the physical burden of management - seemed to be most 45 
bothersome to women. For all CIN-grades, distress disappeared over six months following 46 
colposcopy, suggesting a reassuring effect of gynecological management.  47 
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Introduction 59 
Screening for cervical cancer aims to reduce disease-specific mortality by early detection and 60 
treatment of pre-invasive (cervical intraepithelial neoplasia, CIN) or early invasive disease. 61 
Screen participants with abnormal Pap tests are generally referred for gynecological evaluation 62 
including colposcopy. Previous studies found that colposcopy was stressful for most women. 63 
(1) Not the procedure itself but the prospect of having cancer and risk of dying were the 64 
biggest sources of distress. (2)  65 
Cervical cancer screening is aimed at preventing the disease by finding and treating precursor 66 
lesions, but these precursors are known to often regress. (3) The number of treated precursors 67 
will thus be considerably larger than the number of prevented cases of cervical cancer. 68 
Screening policy thus requires balancing the benefits of preventing cancer by treatment of 69 
lesions that are likely to resolve against the harms of screening. Distress and anxiety due to 70 
screening are such harms. Until 2004 there had been little research on how short-term effects 71 
of screening interventions affect quality of life. (4) While roughly half of the adult women in 72 
Europe are invited to have a smear test at least once every 5 years, of whom between 0.8 and 73 
4.4% are referred to colposcopy every screening round, (5) the extent and duration of adverse 74 
quality of life effects after abnormal Pap test results are still unknown.   75 
We aimed to prospectively assess the effects of colposcopy referral on women’s generic 76 
health-related quality of life (HRQoL) and on (screen-specific) anxiety levels. A female 77 
reference group of screen participants was included as a proxy of HRQoL levels preceding 78 
referral. We compared HRQoL and anxiety outcomes of the study group, referred to as 79 
“colposcopy group”, to those of the reference group. 80 
81 
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Methods 82 
Cervical cancer screening in the Netherlands 83 
In the Dutch national cervical cancer screening program, women aged 30-60 are invited once 84 
every 5 years to have a Pap test. Participation does not entail costs. At the time this study was 85 
conducted, the national uptake rate was 65%, (6) and neither primary HPV screening nor HPV 86 
vaccination had been introduced. In 2009, 96.7% of women who participated had normal 87 
cytological smear results and in one percent Pap tests were of inadequate quality requiring 88 
repeat smears. High-grade cytological abnormalities, including moderately dyskaryotic (Pap 89 
3a2 (7)) or worse, were found in 0.5% to 0.7% and low grade abnormalities, including 90 
borderline or mildly dyskaryotic (Pap 2/3a1) smear results, were found in 1.8% of screen 91 
participants. (6-8)  92 
Women can be referred to gynecological evaluation through two different routes. Following 93 
the screening protocol women whose smear results are moderately dyskaryotic (Pap 3a2) or 94 
worse are immediately referred for colposcopy by a gynecologist. Women with borderline or 95 
mild dyskaryotic smear results (Pap2/3a1) are advised to have triage smears made by their GP. 96 
(7) If these are once again abnormal women are also referred for colposcopy.  97 
If histology results of biopsies taken at colposcopy indicate CIN-grade 2 or worse further 98 
treatment is performed. A more conservative approach is recommended for women diagnosed 99 
with CIN 1 since the majority of these lesions will regress. After two or three consecutive 100 
negative smears women with CIN 1 will return to the national screening program. 101 
 102 
Study design 103 
Between February 2006 and April 2008 a prospective longitudinal cohort study was conducted 104 
in two Dutch hospitals. We aimed at including all women who were referred for gynecological 105 
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evaluation because of abnormal Pap test results in the screening program. Women whose 106 
patient files later showed that they were ineligible were excluded (see Figure 1.) 107 
Women scheduled for colposcopy after abnormal smear results were sent a letter, in which 108 
they were asked for written informed consent to participate in the study, which involved 109 
completion of the attached questionnaire (see below), and 3 following ones after 1, 3 and 6 110 
months (return envelopes were provided). Women were also asked for permission to consult 111 
their patient files and/or the gynecologist for clinical data about colposcopy follow-up. They 112 
were assured that not completing the questionnaires would not have any consequences for 113 
their medical care. No reminders were sent after the initial questionnaire. Once women had 114 
consented in participation in the study we sent reminders for follow-up questionnaires.  A 115 
group of screen participants was included as a reference (see below). Both groups were 29-60 116 
years old. 117 
This study was part of a comprehensive evaluation of the Dutch cervical cancer-screening 118 
program. The medical ethics review committees of the Erasmus University Medical Center 119 
Rotterdam (MEC-2004-099) and of Medical Center Alkmaar (M04-051) approved the research 120 
protocol. 121 
 122 
Respondents’ characteristics 123 
Questions on education, employment, marital status, and having children or not were part of 124 
the initial questionnaire. Educational level was classified as low (primary school or lower 125 
technical education), intermediate or high (college/university degree).  126 
Information about Pap results at referral for gynecological evaluation and about CIN-grade was 127 
available conditional on women having granted permission to consult their patient files and/or 128 
gynecologist.  129 
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In this paper all colposcopy results worse than CIN 1 will be referred to as CIN 2+. The most 130 
severe grade of CIN in the first biopsy after inclusion in this study was used to define the 131 
respondents’ CIN-grades. (9)  132 
 133 
Reference group 134 
We compared HRQoL and anxiety scores of the intervention group to those of a reference 135 
group of 706 screen participants, who had been recruited through the regional screening 136 
organization in Maastricht (10). Data were collected after screening but before women knew 137 
their test result. Reference and study group completed similar measures (see below).  138 
 139 
Content of the questionnaires 140 
Questionnaires included validated measures on generic HRQoL (11), generic anxiety (12), and 141 
screen specific anxiety (13). Generic HRQoL was assessed through the EuroQol classification 142 
(EQ-5D) and the 12-item Short-Form Health Survey (SF-12). The EQ-5D consists of 5 items 143 
(mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression). Scores can be 144 
linked to a utility score with 0 indicating ‘death’ and 1 ‘full health’. (14) The EQ-5D is 145 
complemented by a visual analogue scale on current health, the Valuation of Own Health, 146 
which is anchored by ‘worst imaginable health state’ (0) and ‘best imaginable health state’ 147 
(100). The SF-12 consists of 12 items in the physical and mental domain. Based on these item 148 
scores summary measures for the physical and mental component (PCS-12 and MCS-12) are 149 
constructed, (11) using norm-based methods with a mean of 50 and a standard deviation (SD) 150 
of 10. Age- and sex-adjusted SF-12 norm scores from the Dutch population, including women 151 
who do not participate in the screening program, are available from Statistics Netherlands. 152 
(15) 153 
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Generic anxiety was assessed through the STAI-6 containing 6 items on e.g. feeling at ease or 154 
upset. Higher scores (20-80) indicate higher levels of generic anxiety. (12, 16) STAI-State scores 155 
of over 44 define an individual as highly anxious. (17) 156 
Screen-specific anxiety was measured through the Psychological Consequences Questionnaire 157 
(PCQ), which was developed to assess the consequences of breast screening on emotional, 158 
physical, and social functioning. Corresponding subscales contain 5, 4, and 3 items, 159 
respectively. (13) Ratings for symptoms within each dimension vary from 0 (not at all) to 3 160 
(quite a lot of time). The overall PCQ score ranges from 0-36; (18) higher scores indicate more 161 
dysfunction. We used the Dutch version as adapted by Rijnsburger and colleagues. (19)  162 
 163 
Statistical analyses 164 
In accordance with guidelines, (20) missing items in the STAI-6 and the PCQ were imputed by 165 
respondents’ own average score if they had completed at least 50% of the items. Differences 166 
between the colposcopy and reference groups considering background variables were 167 
assessed using t-tests for continuous variables and Chi-square tests for categorical ones. 168 
Differences considering HRQoL and anxiety scores were assessed using linear regression, 169 
controlling for differences in age. A condition for linear regression is a normal distribution of 170 
residuals. However, this condition is often not met when HRQoL measures are used. Therefore 171 
we inspected the residuals and compared them with the normal distribution. The deviations 172 
we found led us to perform a bootstrap analysis (21) (1,000 replicas) in the program R, (22) 173 
while controlling for differences between groups in age. 174 
Friedman tests were used to assess changes in HRQoL scores in the study group across 175 
multiple measurements. Friedman tests are based on data from those who completed all 176 
assessments. For each measure we report how many women completed it at all four time 177 
points, and we report on the HRQoL and anxiety scores of just those women. We hypothesized 178 
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that more anxiety would be reported at baseline if the initial Pap result was more serious. 179 
Therefore we assessed HRQoL and anxiety by Pap result (Pap2/3a versus Pap 3b or worse), 180 
using t-tests to assess the significance of the differences between groups. We also 181 
hypothesized that the more serious the CIN-grade turned out to be, the more anxiety and 182 
screen specific anxiety would be reported at follow-up assessments, and therefore we 183 
assessed HRQoL and anxiety per CIN group (i.e. no CIN was found versus CIN 1 versus CIN 2+). 184 
We used ANOVA to assess the statistical significances of differences in HRQoL and anxiety 185 
scores between CIN-groups. Statistical analyses were performed using SPSS for Windows, 186 
version 17. 187 
The minimal important difference (MID), indicating clinical relevance, was operationalized as a 188 
difference of at least half a SD. (23) 189 
190 
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Results 191 
154 women completed questionnaires after being referred for gynecological evaluation. Three 192 
of them were too young to have participated in the screening program. We excluded them 193 
from further analyses. After consulting patient files or gynecologists (if women had given us 194 
permission to do so), we found that another 19 women were ineligible since they had not been 195 
referred to the gynecologist after routine Pap tests (n=15) or they had already been having 196 
gynecological check-ups for at least a year (n=4). Thus, 132 women were included for analysis 197 
(see Figure 1, Table 1). Pap test results had been communicated to them by their GP (69%), or 198 
by their GP’s assistant (29%). In two cases the hospital informed these women. Women had 199 
been contacted by telephone (74%), in person (22%) or by letter (5%). There is no protocol 200 
specifying how abnormal PAP results should be communicated to women. 201 
Histological results were known in 115/132 women and were CIN 1 (n=17), CIN 2 (n=32), CIN 3 202 
(n=29), or carcinoma stage 1 (n=1). In 36 women there was no histologically confirmed 203 
neoplasia. These women had been referred with Pap 2 (n=21), Pap 3a (n=13), or Pap 3b (n=2). 204 
In two women CIN-grades were unknown and fifteen women did not grant us permission to 205 
access their patient files or gynecologist. Since their HRQoL and anxiety scores were similar to 206 
those who had routine cervical smears, we included them in the analyses. Management was 207 
known in 117 women. Forty-six out of these women did not receive therapy, , 60/117 were 208 
treated once and  11 women were treated more than once  (11/117), e.g. by LLETX excision 209 
and conisation or they had conisation twice. Table 2 presents the most invasive therapy per 210 
woman, reported per CIN-grade.  211 
Overall, questionnaire response rates were 114 (86%), 110 (83%), and 108 (82%) at 1, 3, and 6 212 
months follow-up. 213 
 214 
Comparison colposcopy group and reference group 215 
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Background variables differed significantly between the colposcopy and the reference group 216 
(Table 1). As expected, women referred for colposcopy (n=132) were younger (40.6 vs. 45.6 217 
years), because low grade CIN is more prevalent in younger age groups. Compared to the 218 
reference group they had more often paid jobs and less often children.  219 
The crude PCS-12 scores of the colposcopy group were significantly higher – which indicates 220 
better physical functioning - than those of the reference group (54 versus 51, Table 3) and than 221 
the age adjusted norm score of 51 for the female Dutch population (Statistics Netherlands). 222 
The MCS-12 scores of the colposcopy group, however, were lower – which indicates poorer 223 
mental functioning - than those of the reference group (47 versus 53, Table 3) and than the 224 
Dutch norm scores of 52 (Statistics Netherlands). Differences remained significant after 225 
controlling for age (Table 3). 226 
Average crude STAI-6 and PCQ scores were higher in the colposcopy group than in the 227 
reference population, indicating more generic and screen specific anxiety in women with 228 
abnormal smear results. Differences in STAI-scores and in two PCQ subscale scores exceeded 229 
the Minimal Important Difference (MID), indicating that the differences between the 230 
colposcopy group and the reference population were of clinical relevance (Table 3).  231 
For all scale scores bootstrap analyses resulted in similar conclusions considering statistical 232 
significance and clinical relevance as the linear regression analyses. 233 
 234 
Generic HRQoL and anxiety: results over time 235 
Changes over time in the EQ-5D utility score, the EQ-5D ’rating of own health’, and the sum 236 
score for physical function (PCS-12) were neither statistically significant nor clinically relevant. 237 
The scores for mental health score (MSC-12), generic anxiety (STAI-6), and screen-specific 238 
anxiety (PCQ) improved over time (p<0.001). Overall, changes over time indicated improved 239 
functioning towards the end of the follow up period. Changes in generic anxiety and in two 240 
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subscales of screen-specific anxiety indicated clinical relevance (Table 4). At baseline, 32% of 241 
the colposcopy group (41/130) reported high anxiety levels (i.e. STAI-6 scores of over 44). This 242 
decreased to 18% (20/112) at 1 month follow-up, and to 14% at 3 and 6 months follow-up 243 
(15/110 and 15/108, respectively). High anxiety was reported by 10% of the reference group. 244 
The significance of the difference between the groups decreased from p<0.001 at baseline to 245 
0.24 at 6 months follow-up. 246 
At 6 months follow-up, HRQoL and generic anxiety scores of the colposcopy group were similar 247 
to those of the reference group, while screen-specific anxiety scores remained worse. 248 
 249 
Generic HRQoL and anxiety over time by initial Pap test result 250 
HRQoL and anxiety were similar in women referred for colposcopy with Pap 2/Pap 3a (at most 251 
moderately dysplastic, n=90) versus women with Pap 3b or worse (at least severely dysplastic, 252 
n=21), data not shown. 253 
 254 
Generic HRQoL and anxiety over time by CIN-grade 255 
In 115 cases CIN-grades were known. Regardless of CIN-grade, generic HRQoL remained at 256 
similar levels throughout follow-up and (screen specific) anxiety decreased over time (Figure 257 
2). With two exceptions, HRQoL and anxiety scores differed significantly between the 3 CIN-258 
groups. 259 
260 
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Discussion 261 
We assessed the HRQoL and anxiety in a cohort of women with abnormal Pap test results who 262 
were referred for gynecological evaluation. At baseline, the colposcopy group reported more 263 
anxiety than the reference group, with differences being clinically relevant. We found that 264 
during follow-up, overall, HRQoL improved in the colposcopy group and their anxiety 265 
decreased over time, irrespective of CIN-grade.  266 
 267 
 The availability of clinical data, which enabled us to discriminate between varying 268 
degrees of abnormalities, is one of the strengths of this prospective study. Also, as 269 
recommended for quality of life research, we used both generic and screen-specific health 270 
measures that had been validated in similar groups as the currently described population. To 271 
enable interpretation of the HRQoL and anxiety scores we included a reference group, which is 272 
recommended but not often done (4). Limitations of this study are the lack of data about the 273 
length of the interval between the receipt of the Pap test results and the colposcopy results, 274 
the response rate being unavailable, and the relatively low number of respondents who were 275 
diagnosed with CIN 1. 276 
 277 
CIN grade 2+ was found in 62 out of 115 women and the positive predictive value (PPV) was 278 
thus 54%, which is comparable to the 49% PPV of a moderately dyskaryotic Pap test in the 279 
Dutch screening program (5).  280 
In 36 women in our cohort (31%) only normal Pap tests and histology results were observed 281 
during follow-up. These so-called false positive test results are inherent to screening programs; 282 
an abnormal test result leads to additional tests and hospital visits and may cause anxiety or 283 
worry, while no abnormalities are found in the end. This group of women, of whom four 284 
received treatment, reported similar HRQoL and higher anxiety levels as who were found to 285 
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have CIN2+, while in the latter group 59 out of 62 women received treatment. Anxiety - and 286 
not the physical burden of management - seemed to be most bothersome to women. In a 287 
review of 210 papers Cullen et al. concluded that affected domains in women with false-288 
positive screening results include distress, fear and worry about having or getting cancer. (4) 289 
This issue becomes even more relevant with the introduction of HPV-screening, since the 290 
specificity of HPV screening is expected to be considerably lower in younger age groups (24). 291 
Twenty years ago most women interpreted the term precancer as ‘early cancer’. (25) Also 292 
more recently, mildly abnormal smear results were misinterpreted as actually having cancer 293 
(26, 27) which will lead to more anxiety. (27) We therefore recommend to provide women 294 
who have abnormal smear test results with clear written information about the meaning of 295 
this result, stressing that the abnormal test result does not indicate that they have cancer, and 296 
to check in person or by phone whether this information was properly understood. 297 
 In a previous study, women not complying with follow-up protocols reported the 298 
highest anxiety scores. (28) Since we only included women who did participate in follow-up 299 
protocols, we probably arrived at an underestimation of women’s anxiety, even more so 300 
because pathologically high levels of anxiety and worry apparently lead to low screening rates. 301 
(4) 302 
 The negative impact on mental health of abnormal smear results was found to be not 303 
of a lasting or serious nature in the majority of women. (29, 30) However, in a cross-sectional 304 
study among 270 women, addressed at 6-24 months after the initially abnormal Pap test 305 
result, our research group showed that borderline and mildly dyskaryotic smear results were 306 
consistently associated with considerable excess anxiety. (31)  307 
308 
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CONCLUSION 309 
We conclude that referral for gynecological evaluation after abnormal PAP-test results 310 
negatively impacted mental health. Anxiety - and not the physical burden of management - 311 
seemed to be most bothersome to women, which confirms earlier literature. Irrespective of 312 
CIN-grade, this negative effect on mental health diminished over time and had washed out at 6 313 
months after baseline. Possibly, this indicates that management had a reassuring effect and 314 
led to reduced anxiety levels. We recommend carefully choosing cut-off strategies for referral 315 
to colposcopic evaluation. Also, clear communication about the meaning of false-positive test 316 
results is needed with women invited to participate in screening and with women who have 317 
abnormal test results, so they will understand what is going on – and especially what is not.    318 
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 Table 2 Most invasive treatment per woman, reported per CIN-grade 360 
Table 3 Generic Quality of Life scale scores (SD) in women referred to the gynecologist for 361 
 colposcopy, shortly after their abnormal test results and in a reference population of 362 
 screen participants. Statistical significance of differences between groups was age-363 
 adjusted. 364 
Table 4 Time trend analysis (repeated measures) of women with an abnormal Pap test result 365 
(colposcopy group); starting before the first consultation with the gynecologist, plus 366 
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follow-up assessments at 1, 3, and 6 months later, and the statistical significance of 367 
changes over that time period.  368 
Figure 2 Health-related quality of life and anxiety scores per CIN-stage at four assessments. 369 
 370 
371 
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Table 1 Background characteristics of the colposcopy group, observed scores in numbers and 455 
percentages, unless otherwise indicated, compared with a reference group of screen participants. 456 
 Colposcopy group 
n=132 
Screen  
participants  
n=706 
 
 
p-value 
Age (years)   <0.001 
 Average (SD) 40.6 (8.2) 45.6 (9.3)  
 Median 
 Range 
40.2 
29-60 
45.1 
29-60 
 
Missing 4 1  
    
Education (%)   0.06 
 Low education 21 (17) 144 (23)  
 Medium  77 (62) 323 (50)  
 High  26 (21) 174 (27)  
Missing 8 65  
    
Employment status (%)   0.03 
 Paid job 92 (81) 419 (67)  
 Housewife/unpaid job/student 16 (14) 142 (23)  
 No job 6 (5) 49 (8)  
 Retired 0 13 (2)  
Missing 18 83  
    
Marital status (%)   0.03 
 Married/cohabiting 92 (72) 567 (81)  
 Living without partner 36 (28) 137 (20)  
Missing 4 2  
    
Children (%)   0.002 
 No 40 (32) 130 (20)  
 Yes 84 (68) 528 (80)  
Missing 8 48  
 Average no. of children 2 2  
    
Country of birth (%)   <0.001 
 the Netherlands 120 (92) 627 (99)  
 otherwise 11 (8) 4 (1)  
Missing 1 64  
 457 
458 
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Table 2 Most invasive treatment per woman, reported per CIN-grade 459 
 460 
 Most invasive therapy per woman, n (%) No 
therapy 
 
Total Cryotherapy LLETZ excision Conisation Uterus extirpation 
CIN-grade       
No neoplasia found 1 (1%) 0 (-) 1 (1%) 2 (2%) 32 (27%) 36 (31%) 
CIN=1 4 (3%) 2 (2%) 1 (1%) 0 (-) 10 (9%) 17 (15%) 
CIN2+ 20 (17%) 29 (25%) 7 (6%) 3 (3%) 3 (3%) 62 (53%) 
Unknown CIN-grade 0 (-) 1 (1%) 0 (-) 0 (-) 1 (1%) 2 (2%) 
Total 25 (21%) 32 (27%) 9 (8%) 5 (4%) 46 (39%) 117 (100%) 
 461 
 462 
463 
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Table 3 Generic Quality of Life scale scores (SD) in women referred to the gynaecologist for colposcopy, 464 
 shortly after their abnormal test results and in a reference population of screen participants. 465 
 Statistical significance of differences between groups was age-adjusted. 466 
 467 
 Colposcopy 
group 
n=132 
Screen 
participants 
n= 706 
p-value 
 
Generic health-related quality of life   
EuroQol utility, EQ-5D (0-1) 0.90 (0.14) 0.90 (0.18) 0.85 
EuroQol , Rating of own health (0-100) 80 (12) 81 (13) 0.46 
    
SF-12 (0-100)    
 Sumscore physical (PCS-12) 54 (8) 51 (10) 0.04 
 Sumscore mental (MCS-12) 47 (12) 53 (9) <0.001 
    
Generic Anxiety 
STAI-6 (20-80) * 
 
41 (12) 
 
33 (10) 
 
<0.001 
Range 20-73 20-77  
Highly anxious (STAI score >44), n (%) 41 (32%) 70 (10%) <0.001 
    
Screen-Specific Anxiety    
PCQ    
 Emotional Scale (0-15)  4 (4) 1 (2) <0.001 
 Physical Scale (0-12) * 2 (2) 0 (1) <0.001 
 Social Scale (0-9) * 2 (2) 0 (1) <0.001 
 Total Score (0-36) * 8 (7) 2 (4) <0.001 
 Range Total Score 0-29 0-30  
 468 
EuroQol and SF-12: higher scores indicate better functioning 469 
STAI-6 and PCQ: higher scores indicate worse functioning. 470 
* differences exceeded the minimal important difference (MID), indicating clinical relevance  471 
472 
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Table 4 Time trend analysis (repeated measures) of women with an abnormal Pap test result 473 
(colposcopy group); starting before the first consultation with the gynaecologist, plus follow-up 474 
assessments at 1, 3, and 6 months later, and the statistical significance of changes over that 475 
time period.  476 
 Shortly after 
suspicious 
smear  
n=132 
At 1 month 
follow-up  
n=114 
At 3 months 
follow-up 
n=110 
At 6 months 
follow-up 
n=108  
 
 
p-
value* 
No. of  
women who 
completed 
measure all 
4 times 
 
 
Inter-
pretation  
Generic health-related quality of life       
EuroQol utility, EQ-5D (0-1) 0.91 (0.14) 0.90 (0.15) 0.93 (0.15) 0.90 (0.21) 0.16 95 Similar 
EuroQol Rating of own health (0-100) 81(12) 77 (18) 80 (17) 78 (18) 0.08 95 Similar 
        
SF-12 (0-100)        
 Sumscore physical (PCS-12) 54 (9) 53 (9) 53 (8) 53 (10) 0.27 77 Similar 
 Sumscore mental (MCS-12) 50 (10) 49 (11) 52 (10) 53 (9) <0.001 77 Improved 
        
Generic Anxiety 
STAI-6 (20-80) * 
 
40 (11) 
 
37 (13) 
 
33 (9) 
 
34 (10) 
 
<0.001 
 
96 
 
Improved 
        
Screen-specific Anxiety        
PCQ         
 Emotional Scale (0-15)  4 (4) 3 (3) 2 (3) 2 (3) <0.001 96 Improved 
 Physical Scale (0-12) ** 2 (2) 2 (3) 1 (2) 1 (2) <0.001 96 Improved 
 Social Scale (0-9) ** 2 (2) 2 (2) 1 (2) 1 (2) <0.001 96 Improved 
 Total Score (0-36) ** 7 (7) 6 (7) 4 (6) 3 (6) <0.001 96 Improved 
* Statistical significance of differences was calculated using Friedman tests, including only respondents 477 
that completed all four assessments. HRQoL and anxiety scale scores are reported of those who 478 
completed that specific scale at each assessment. 479 
** Differences between first and fourth assessment exceed the minimal important difference (MID), 480 
indicating clinical relevance  481 
 482 
EuroQol and SF-12: higher scores indicate improved functioning 483 
STAI-6 and PCQ: higher scores indicate poorer functioning. 484 
485 
 
 
26 
Figure 1. Flowchart of study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 of the 132 women (86%) completed the 
second assessment at 1 month after baseline. 
110 of the 132 women (83%) completed the 
third assessment at 3 months after baseline.  
108 of the 132 women (82%) completed the 
fourth assessment at 6 months after baseline.  
22 women were excluded from analyses 
since they had not been referred for 
gynecological evaluation because of a 
recent abnormal Pap test result (n=19), or 
their age was below the threshold of the 
national cervical cancer screening program 
(n=3). 
132 women were included in the analyses, of 
whom 117 granted us permission to access their 
files and/or their treating gynecologist. 
154 consecutive patients completed the 
baseline questionnaire. 
 
Women who were referred to a gynecologist 
because of abnormal Pap smear results were 
addressed with a baseline questionnaire.  
 486 
